Final Results for the year ended 30 June 2011

BIOVENTIX PLC                                 

                 FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2011                 

                               13 SEPTEMBER 2011                               


The Chairman and the Chief Executive present their statement for the period.

We are delighted to report the results for the year ended 30 June 2011.
Revenues for the period of £1,973,542 (2010 : £1,578,162) have grown by 25%.
The growth in sales to the multinational diagnostics companies that form
Bioventix's customer base is due to an increased supply of purified antibody
products for customers' research and development ("R&D"), and commercial use
and increased royalties from established antibody products. Profit before tax
of £1,083,620 (2010 : £682,706) has increased through a combination of the
growth in revenues and controlling of the cost base of the company. Cash
balances at 30 June 2011 were £1,531,644 (2010 : £1,349 084).

One of the most exciting developments for the company has been the vitamin D
project which has been the subject of intensive internal R&D since the summer
of 2008. A leading antibody called vitD3.5H10 has moved into large scale
manufacturing at the company in order to supply increased quantities of
antibody required for our customers' own R&D use. Revenue from the supply of
this product has been generated for the first time during the period. No major
licensing deals have yet been concluded, however, the Directors are optimistic
about the future value of this particular antibody and anticipate that
significant licensing deals will be forthcoming in the future.

The company has continued with its own R&D activities aimed at augmenting the
pipeline of future antibodies for commercialisation at Bioventix's customers.

The continued success of the company is based on the ability to create and
manufacture unique antibodies in a global and competitive environment. This is
made possible by the creativity and focus of the scientists and support staff
at the company and we would like to thank them for their efforts which have
underpinned our success.

The Board of Bioventix is pleased to declare a final dividend of 6.6p per
Ordinary share. The shares will be marked ex-dividend on 21 September 2011 and
the dividend will be paid on 3 October 2011 to shareholders on the register at
close of business on 23 September 2011.

SpringHill BioVentures (SBV) continues to hold a substantial majority stake in
the company. The board believes that SBV will distribute its shares to
individual shareholders as part of its fund exit within the next 12 months.


P Harrison
Chief Executive Officer

I J Nicholson
Non-Executive Chairman


For further information, please contact:

Bioventix plc
Peter Harrison
Tel: [phone]

Keith, Bayley, Rogers & Co. Limited
David Coffman
Tel: [phone]

About Bioventix plc

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies.

Bioventix is based in Farnham, UK and its shares (BVXP) were admitted to
trading on PLUS-quoted in April 2010.

                     PUBLICATION OF NON-STATUTORY ACCOUNTS                     

The financial information set out in this announcement does not constitute
statutory financial statements for the year ended 30 June 2011 or 30 June 2010.
The reports of the auditor on the statutory financial statements for each of
the years ended 30 June 2011 and 30 June 2010 were (i) unqualified; (ii) did
not include references to any matters to which the auditor drew attention by
way of emphasis without qualifying their report; and (iii) did not contain
statements under section 498(2) or (3) of the Companies Act 2006. The statutory
financial statements for the year ended 30 June 2010 have been delivered to the
Registrar of Companies. The statutory financial statements for the year ended
30 June 2011 will be delivered to the Registrar of Companies following the
Company's Annual General Meeting


                            PROFIT AND LOSS ACCOUNT                            

                        FOR THE YEAR ENDED 30 JUNE 2011                        

                                                             2011          2010
                                                                               
                                               Note             £             £
                                                                               
TURNOVER                                                1,973,542     1,578,162
                                                                               
Cost of sales                                           (236,315)     (197,309)
                                                                               
GROSS PROFIT                                            1,737,227     1,380,853
                                                                               
Administrative expenses                                 (657,629)     (605,782)
                                                                               
Exceptional costs of listing on PLUS Market                     -      (95,844)
                                                                               
Total administrative expenses                           (657,629)     (701,626)
                                                                               
Other operating income                                          -            75
                                                                               
OPERATING PROFIT                                        1,079,598       679,302
                                                                               
Interest receivable and similar income                      4,022         3,404
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE                    1,083,620       682,706
TAXATION                                                                       
                                                                               
Tax on profit on ordinary activities                    (199,161)     (118,285)
                                                                               
PROFIT FOR THE FINANCIAL YEAR                             884,459       564,421
                                                                               

Earnings per share

Basic                                                      17.59p        11.23p
                                                                               
Diluted                                                    17.59p        11.23p

All amounts relate to continuing operations.


There were no recognised gains and losses for 2011 or 2010 other than those
included in the Profit and loss account.


                                 BALANCE SHEET                                 

                              AS AT 30 JUNE 2011                               

                                                     2011                  2010
                                                                               
                                Note         £          £                      
                                                                               
FIXED ASSETS                                                                   
                                                                               
Intangible assets                                  50,000                70,000
                                                                               
Tangible assets                                   448,871               463,690
                                                                               
                                                  498,871               533,690
                                                                               
CURRENT ASSETS                                                                 
                                                                               
Stocks                                  70,743                90,175           
                                                                               
Debtors                                766,755               573,992           
                                                                               
Cash at bank and in hand             1,531,644             1,349,084           
                                                                               
                                     2,369,142             2,013,251           
                                                                               
CREDITORS: amounts falling due       (184,383)             (173,992)           
within one year                                                                
                                                                               
NET CURRENT ASSETS                              2,184,759             1,839,259
                                                                               
TOTAL ASSETS LESS CURRENT LIABILITIES           2,683,630             2,372,949
                                                                               
PROVISIONS FOR LIABILITIES                                                     
                                                                               
Deferred tax                                      (6,237)               (7,173)
                                                                               
NET ASSETS                                      2,677,393             2,365,776
                                                                               
CAPITAL AND RESERVES                                                           
                                                                               
Called up share capital                           251,269               252,500
                                                                               
Capital redemption reserve                          1,231                     -
                                                                               
Profit and loss account                         2,424,893             2,113,276
                                                                               
SHAREHOLDERS' FUNDS                             2,677,393             2,365,776


                              CASH FLOW STATEMENT                              

                        FOR THE YEAR ENDED 30 JUNE 2011                        

                                                             2011          2010
                                                                               
                                               Note             £             £
                                                                               
Net cash flow from operating activities                   966,094       640,967
                                                                               
Returns on investments and servicing of                     4,022      (94,096)
finance                                                                        
                                                                               
Taxation                                                (203,976)     (149,195)
                                                                               
Capital expenditure and financial investment             (10,738)      (31,062)
                                                                               
Equity dividends paid                                   (524,117)     (202,000)
                                                                               
CASH INFLOW BEFORE FINANCING                              231,285       164,614
                                                                               
Financing                                                (48,725)             -
                                                                               
INCREASE IN CASH IN THE YEAR                              182,560       164,614


         RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS/DEBT         

                        FOR THE YEAR ENDED 30 JUNE 2011                        

                                                             2011          2010
                                                                               
                                                                £             £
                                                                               
Increase in cash in the year                              182,560       164,614
                                                                               
CHANGE IN NET DEBT RESULTING FROM CASH FLOWS              182,560       164,614
                                                                               
Debt converted to equity                                        -     1,071,436
                                                                               
MOVEMENT IN NET DEBT IN THE YEAR                          182,560     1,236,050
                                                                               
Net funds at 1 July 2010                                1,349,084       113,034
                                                                               
NET FUNDS AT 30 JUNE 2011                               1,531,644     1,349,084



The Directors of Bioventix plc accept responsibility for this announcement